Aurora Cannabis (ACB)
(Delayed Data from NSDQ)
$5.98 USD
+0.44 (7.94%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $5.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.98 USD
+0.44 (7.94%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $5.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.
Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Apyx Medical (APYX) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.
Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.
Invest Carefully in Rosy But Risky Marijuana Industry
by Nalak Das
The much-awaited Cannabis Banking Bill was finally passed by the House Financial Services Committee on Mar 28.
Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?
by Zacks Equity Research
Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.
Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.06, marking a +0.22% move from the previous day.
Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.
Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
by Zacks Equity Research
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
by Zacks Equity Research
Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
by Zacks Equity Research
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
by Zacks Equity Research
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Should You Buy Lottery Stocks?
by Tracey Ryniec
Like playing the lottery, some stocks lure in investors with the promise of possible riches.
Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
by Zacks Equity Research
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.05, marking a -1.95% move from the previous day.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $8.96 in the latest trading session, marking a +0.9% move from the prior day.
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.01, marking a -1.74% move from the previous day.